Production Capacity and Expansion - The company expanded its production capacity to 13,500 tons/year for gelatin and 4,300 tons/year for collagen, but faces sales risks due to market conditions and inventory levels [9]. - The company plans to expand its production capacity with new projects, including a 3,500-ton gelatin construction project and a 2,000-ton collagen project [31]. - The company plans to expand its capsule production capacity from 30 billion to 60 billion capsules over the next three years, indicating strong growth potential [72]. - The company has committed to invest 114,814.05 million RMB in various projects, with a significant portion allocated to the gelatin expansion project [170]. Financial Performance - The company's operating revenue for 2021 was ¥612,165,671.91, representing a 36.39% increase compared to ¥448,827,791.89 in 2020 [31]. - The net profit attributable to shareholders for 2021 was ¥36,484,130.69, a significant increase of 97.74% from ¥18,450,301.36 in 2020 [31]. - The net profit after deducting non-recurring gains and losses was ¥26,920,029.36, up 127.03% from ¥11,857,395.88 in 2020 [31]. - The total assets at the end of 2021 reached ¥2,112,240,503.24, marking a 48.97% increase from ¥1,417,934,200.36 at the end of 2020 [31]. - The net cash flow from operating activities for 2021 was ¥51,501,086.21, a decrease of 18.42% from ¥63,129,603.25 in 2020 [31]. Product Development and Innovation - In 2021, the company launched new products including beef bone collagen peptides and collagen protein sodium hyaluronate vitamin C powder, with plans for further product releases in 2022 [12]. - The company is focusing on technological innovation and product development in the fields of gelatin and collagen to enhance its competitive edge [48]. - The company is actively developing new products and enhancing its market presence, including launching new products and utilizing celebrity endorsements [48]. - The company has successfully developed a new collagen protein product, "shredded meat" plant-based product, and has made significant progress in the development of ultra-low endotoxin gelatin preparation technology [115]. Market Strategy and Presence - The company aims to strengthen its market presence by establishing trade offices in cities like Hangzhou, Shanghai, and Qingdao to boost sales of raw collagen products [9]. - The company is implementing a "Collagen+" strategy to enhance brand visibility and market share, including the use of celebrity endorsements [13]. - The company is actively expanding its market presence by optimizing product structure and launching new products, while enhancing channel and brand development [58]. - The company plans to enhance its online and offline sales channels, leveraging e-commerce and live streaming platforms to boost brand visibility [181]. Research and Development - The company has invested significantly in R&D, ranking among the top in the industry for new technologies and processes related to collagen and its derivatives [81]. - The company has established multiple research and development platforms, including key laboratories and innovation centers in Inner Mongolia and Qingdao [81]. - The company is collaborating with research institutions to enhance its R&D capabilities, particularly in the field of collagen peptides and their applications [88]. - The company is committed to maintaining high standards in product safety and efficacy, as demonstrated by its research on the toxicological safety of collagen peptides [96]. Acquisitions and Partnerships - The acquisition of Yiqing Bio has been integrated into the company's consolidated financial statements, expanding its operational scale and product range [7]. - The company acquired 60% of Qingdao Yiqing Biotechnology Co., Ltd. on November 30, 2021, which specializes in the production and sales of medicinal capsules, enhancing its position in the biopharmaceutical supply chain [135]. - The company has established partnerships with several universities and research institutions to support the development of bio-organic fertilizers and other products [116]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a focus on complementary businesses [92]. Governance and Compliance - The company has established a sound governance structure that complies with the regulations set forth by the China Securities Regulatory Commission [197]. - The board of directors consists of 7 members, including 3 independent directors, and operates in compliance with legal and regulatory requirements [196]. - The company actively communicates with stakeholders, ensuring the protection of their legal rights and interests [197]. - There are no significant discrepancies between the company's governance practices and the relevant laws and regulations [197]. Sustainability and Social Responsibility - The company is focused on sustainable practices, promoting a circular economy and resource recycling systems in line with national policies [56]. - The organic fertilizer segment is gaining traction due to government policies promoting sustainable agriculture, with the company positioned to benefit from this trend [51]. - The company is entering the fertilizer market with a resource utilization project, leveraging unique product advantages to capture opportunities in the agricultural sector [188]. - The company is committed to fostering a corporate culture that aligns with its parent company, enhancing employee engagement and operational efficiency [190].

包头东宝生物技术股份有限公司 2022 年第一季度报告全文 证券代码：300239 证券简称：东宝生物 公告编号：2022-018 包头东宝生物技术股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 228,169,864.35 | 138,178,161.95 | 65.13% | | 归属于上市公司股东的净利润（元） | 23,723,318.02 | 4,6 ...

包头东宝生物技术股份有限公司 2021 年第三季度报告 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 证券代码：300239 证券简称：东宝生物 公告编号：2021-095 包头东宝生物技术股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 135,596,826.05 | 18.65% | 412,267,239.59 | 36 ...

包头东宝生物技术股份有限公司 2021 年半年度报告全文 包头东宝生物技术股份有限公司 2021 年半年度报告 2021-076 2021 年 08 月 1 包头东宝生物技术股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人王军、主管会计工作负责人郝海青及会计机构负责人(会计主管 人员)杜丽声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 一、经营规模扩大可能带来管理风险 公司目前已形成一体多翼模式，经营管理规模、业务范围进一步扩大，产 品品类进一步丰富，对公司管理和运营提出了新的挑战。尤其是在子公司管理、 市场推广、新业务团队搭建等方面，如果不能与业务发展同步，公司可能会面 临一定的管理风险，从而可能对上市公司利润形 ...

证券代码：300239 证券简称：东宝生物 公告编号：2021-064 包头东宝生物技术股份有限公司 关于举行2021年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司（以下简称"公司"）定于 2021 年 8 月 4 日（星期三）15：00—17：00 采用网络远程方式举行 2021 年投资者网上集体接 待日活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上 平台采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 以 登 录 " 全 景 · 路 演 天 下 " （http://rs.p5w.net）参与本次互动交流。 欢迎广大投资者积极参与。 特此公告。 包头东宝生物技术股份有限公司 董事会 2021 年 7 月 29 日 ...

Financial Performance - The company's operating revenue for Q1 2021 was ¥138,178,161.95, representing a 53.56% increase compared to ¥89,993,866.50 in the same period last year[8] - Net profit attributable to shareholders was ¥4,628,670.64, up 36.59% from ¥3,508,687.40 in the previous year[8] - Basic and diluted earnings per share increased to ¥0.0089, reflecting a growth of 36.92% compared to ¥0.0067 in the previous year[8] - The company's net profit after deducting non-recurring gains and losses decreased by 10.31% year-on-year to CNY 2,282,380.49[23] - The net profit for the first quarter of 2021 was CNY 4,975,091.72, an increase of 76% compared to CNY 2,831,763.81 in the same period last year[63] - Operating profit reached CNY 6,343,741.66, up from CNY 3,525,775.07, reflecting a growth of 80% year-over-year[63] - The total profit amounted to CNY 6,347,193.29, compared to CNY 3,507,468.36 in the previous year, indicating a 81% increase[63] Cash Flow - The net cash flow from operating activities improved significantly to ¥3,278,714.69, a 209.95% increase from a negative cash flow of ¥2,350,379.61 in the same period last year[8] - Cash flow from operating activities generated a net amount of CNY 3,278,714.69, a significant recovery from a negative cash flow of CNY -2,982,028.40 in the prior year[67] - The net cash flow from investment activities was -11,965,847.06 CNY in Q1 2021, compared to -8,250,707.52 CNY in Q1 2020, indicating a decline in investment cash flow[71] - The net cash flow from financing activities was -8,059,928.22 CNY in Q1 2021, contrasting with a positive net cash flow of 18,883,375.32 CNY in Q1 2020[71] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,425,806,725.14, a slight increase of 0.56% from ¥1,417,934,200.36 at the end of the previous year[8] - Total liabilities increased to CNY 422,506,385.20 from CNY 419,750,969.84, reflecting a growth of about 0.60%[51] - The company's equity attributable to shareholders reached CNY 994,642,078.94, up from CNY 989,956,482.67, indicating an increase of approximately 0.17%[52] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,374[12] - The largest shareholder, Inner Mongolia Dongbao Economic and Trade Co., Ltd., held 26.60% of the shares, totaling 138,823,422 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Government Subsidies - The company received government subsidies amounting to ¥2,696,854.35, primarily related to asset-related government grants[9] - Cash received from government subsidies increased by 48.18% to CNY 2,599,306.80 compared to the previous period[22] Operational Costs and Expenses - The gross profit margin decreased due to a significant rise in operating costs, which amounted to ¥121,070,448.96, reflecting a 66.23% increase from ¥72,831,984.74[20] - Tax expenses increased by 79.48%, amounting to ¥2,181,946.29, due to higher sales leading to increased VAT and other taxes[20] - Selling expenses decreased by 39.30% to ¥2,135,151.99, as transportation costs were reclassified into operating costs under new revenue recognition standards[20] - Financial expenses surged by 135.50%, reaching ¥2,085,829.42, primarily due to increased interest on working capital loans[20] Future Outlook and Strategy - The company plans to continue expanding its product lines and market reach, focusing on gelatin and collagen products[20] - Future guidance indicates a positive outlook for revenue growth driven by increased sales volume and market demand[20] - The company plans to focus on innovation, operational strengthening, and new product promotion to drive growth[29] - The company aims to enhance product quality and development by collaborating with research institutions and downstream customers, focusing on new consumption trends and market expansion[31] Research and Development - The company is advancing the development of ultra-low endotoxin gelatin, aimed at applications in medical devices and tissue engineering[23] - A collaboration project with Shanghai Lanwei Medical Technology Co., Ltd. has been signed to expand the application of gelatin in high-value sectors[25] - The R&D project for artificial meat products has completed development, with a small production line in trial operation[27] - The company has initiated research on bioactive peptides derived from collagen, targeting applications in various fields[28] Production Capacity and Risks - The company has expanded its collagen production capacity to 13,500 tons/year for gelatin and 4,300 tons/year for collagen, but faces sales risks due to market conditions affecting full production ramp-up[30] - The company is addressing raw material procurement risks by optimizing supply chain management and exploring new sourcing channels[32] Compliance and Management - The company has received the "High-tech Enterprise Certificate" from relevant authorities, reaffirming its status as a high-tech enterprise[35] - The company is committed to improving its management efficiency and operational capabilities in response to the challenges posed by its expanded business scale[30] - The company has established a pandemic response team to mitigate the impact of COVID-19 on its operations and supply chain[34]

Financial Performance - The company's operating revenue for 2020 was approximately ¥448.83 million, a decrease of 8.79% compared to the previous year[30]. - The net profit attributable to shareholders for 2020 was approximately ¥18.45 million, representing a decline of 43.94% year-over-year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥11.86 million, down 55.21% from the previous year[30]. - The net cash flow from operating activities for 2020 was approximately ¥63.13 million, a significant increase of 251.86% compared to the previous year[30]. - The total assets at the end of 2020 amounted to approximately ¥1.42 billion, reflecting a growth of 7.80% year-over-year[30]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥989.96 million, showing a slight increase of 0.06% compared to the previous year[30]. - The basic earnings per share for 2020 were ¥0.0353, a decrease of 45.61% from the previous year[30]. - The diluted earnings per share for 2020 were also ¥0.0353, reflecting the same decline of 45.61% year-over-year[30]. - The company reported a quarterly revenue increase, with Q4 2020 revenue reaching approximately ¥147.76 million, the highest for the year[32]. - The company achieved total operating revenue of CNY 448,827,791.89, a decrease of 8.79% year-on-year[47]. Production Capacity and Expansion - The company's collagen production capacity reached 13,500 tons/year for gelatin and 4,300 tons/year for collagen, with potential short-term profit impacts due to fixed costs after project completion[8]. - The company has initiated projects to expand gelatin production capacity from 3,500 tons to 7,000 tons, which was affected by the pandemic[48]. - The company completed a 2000-ton collagen protein project and upgraded its production line from 1000 tons to 2300 tons, enhancing product quality and expanding capacity[77]. - The company plans to expand its collagen protein peptide supplement production capacity from 1,000 tons to 2,300 tons[123]. - The annual average net profit for the 2,000 tons collagen project is projected to be CNY 22.86 million once fully operational[132]. - The first-year capacity utilization rate for the 2,000 tons collagen project is expected to reach 60%, with an estimated net profit of CNY 8.319 million[132]. Research and Development - The company is committed to developing new products and enhancing quality to meet the evolving consumer demands in the market[9]. - The company is actively involved in the research and development of new technologies and products to lead innovation in the collagen field[50]. - Research and development expenditures have surged by 159.62% compared to the previous period, indicating a strong commitment to innovation[52]. - The company has obtained 19 authorized patents, including 11 Chinese invention patents and 1 U.S. invention patent, showcasing its focus on technological advancement[58]. - The company is focusing on enhancing product quality, R&D capabilities, and expanding application fields and marketing channels[44]. - The company is focusing on developing new health products in collaboration with top universities and research institutions, including projects related to low-endotoxin and antimicrobial peptides[148]. Market Strategy and Sales Channels - The company plans to enhance its market expansion efforts by collaborating with educational institutions and research organizations, aiming for breakthroughs in retail sales of collagen products[9]. - The company has established a sales platform in Hangzhou to promote retail product channel development and business expansion, leveraging both online and offline resources[14]. - The company is exploring new sales channels and partnerships in economically developed areas to improve retail product sales efficiency[14]. - The company is actively developing diverse sales channels, including retail and e-commerce, to capitalize on the growing health market[78]. - The company aims to leverage its trademark portfolio to enhance market penetration and brand recognition in competitive sectors[65]. Financial Management and Investments - The company has not planned to distribute cash dividends or issue bonus shares for the year[16]. - The company reported a total distributable profit of approximately 123.63 million RMB for the year[160]. - The company has committed to not infringing on the interests of shareholders, particularly minority shareholders, by not distributing dividends[164]. - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[165]. - The company has made commitments to not interfere with its operational management and to protect its interests[176]. - The company will strictly implement its dividend policy to ensure shareholder returns[178]. Risk Management and Operational Efficiency - The company is focusing on optimizing its supply chain management to mitigate procurement price volatility risks, especially for key raw materials[12]. - The company is addressing management risks associated with its expanded operational scale by optimizing management models and forming core business teams[6]. - The company is committed to maintaining high standards in product safety and efficacy, as demonstrated by its research on the toxicological safety of collagen products[63]. - The company is committed to improving production, quality, and supply chain management while accelerating the certification process for key products and licenses[152]. Regulatory Compliance and Corporate Governance - The company has committed to ensuring that any new regulatory requirements from the China Securities Regulatory Commission will be met[167]. - The company has established a linkage between the execution of its compensation system and the measures to fill immediate returns[168]. - The company confirmed that all commitments made to minority shareholders were fulfilled on time[182]. - The company will comply with the latest regulations from the China Securities Regulatory Commission regarding shareholder and executive stock reduction[173]. Industry Trends and Market Position - The health and biopharmaceutical industry is experiencing rapid growth, supported by government policies and increasing consumer health awareness[49]. - The company’s market position is expected to improve as domestic technology levels and brand recognition increase, indicating significant growth potential in the collagen market[51]. - The company is benefiting from favorable government policies and the rapid development of the health service industry, which is expected to create better market opportunities for its collagen business[141]. - The company is positioned as a leading enterprise in the collagen industry, with a comprehensive production and sales system covering the entire collagen industry chain[140].

包头东宝生物技术股份有限公司 2020 年第三季度报告全文 包头东宝生物技术股份有限公司 2020 年第三季度报告 2020-089 2020 年 10 月 1 包头东宝生物技术股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王军、主管会计工作负责人郝海青及会计机构负责人(会计主管 人员)杜丽声明：保证季度报告中财务报表的真实、准确、完整。 2 包头东宝生物技术股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期末 | | | 上年度末 | | | 本报告期末比上年度 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 末增减 | | | ...

Production Capacity and Expansion - The company has expanded its gelatin production capacity from 3,500 tons to 7,000 tons, with total annual gelatin capacity reaching 13,500 tons and collagen capacity at 3,000 tons[6]. - The company's construction of a 2,000-ton collagen production project has been completed, resulting in a 48.69% decrease in construction in progress compared to the beginning of the period[45]. - The annual production capacity for gelatin reached 13,500 tons, while collagen protein capacity was 3,000 tons following the launch of the fundraising project[61]. - The company is currently constructing several projects, including a 20,000-ton collagen protein peptide supplement production project, which is in the preparation stage[92]. - The company has committed to an investment project for the construction of a new gelatin production facility with an annual capacity of 3,500 tons, with a total investment of CNY 25,357 million, achieving 98.83% of the planned investment by the end of the reporting period[97]. Financial Performance - The company reported total operating revenue of ¥186,782,124.41, a decrease of 19.15% compared to the same period last year[26]. - Net profit attributable to shareholders was ¥6,779,047.92, down 61.70% year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥3,844,553.20, a decline of 74.09% compared to the previous year[26]. - Basic earnings per share decreased to ¥0.0129, down 64.17% from the previous year[26]. - The weighted average return on net assets was 0.69%, a decrease of 1.35% compared to the previous year[26]. Market Strategy and Product Development - The company aims to strengthen its brand "Yuan Su Bone Peptide" in the senior market and has introduced new products such as "multi-flavor collagen peptide powder" and "fish collagen" to diversify its product line[8]. - The company is focusing on expanding into high-growth health markets, including nutrition and bone health, to capitalize on consumer trends[7]. - The company is enhancing its online marketing efforts, expanding into cross-border e-commerce and self-media channels to optimize its sales system[62]. - The company is focusing on market expansion in the fields of medicine, health, food, and beauty, aiming for diversified applications of collagen[60]. - The company has successfully developed new products, including a composite emulsifier and a new artificial meat project, indicating a diversification of collagen applications[51]. Challenges and Risks - The company has faced procurement risks due to increased costs from upstream suppliers and the ongoing impact of the pandemic, prompting it to strengthen its procurement strategies and explore new supply channels[11]. - The company faced challenges due to the COVID-19 pandemic, resulting in reduced demand from downstream customers and decreased international trade[40]. - Increased production costs were attributed to supply chain disruptions and higher procurement costs during the pandemic[41]. - The company emphasizes the importance of innovation and new product development to mitigate procurement price volatility risks[11]. Corporate Social Responsibility and Governance - The company has committed to corporate social responsibility by supporting pandemic relief efforts through donations and material support[13]. - The company emphasizes strict information disclosure and investor relations management, ensuring orderly operations under the new registration system[72]. - The company is committed to fulfilling its obligations regarding immediate return measures to protect investor interests[120]. - The company has made commitments to prevent any interference in its operational management by major shareholders[120]. Research and Development - The company has a strong focus on technological innovation, with 17 authorized patents, including 9 Chinese invention patents and 1 US invention patent[52]. - The company is committed to increasing R&D investment to support the industrialization and marketization of innovative projects[51]. - Research and development expenses were ¥6,415,004.61, down 41.99% from ¥11,058,175.06 in the previous year, due to the scheduling of R&D projects[74]. Environmental Compliance - The company has established an Environmental Protection Management Committee to oversee environmental compliance and pollution control measures[147]. - The company has not reported any major environmental incidents or exceedances of discharge limits during the reporting period[146]. - The company conducted annual emergency drills for environmental incidents to ensure preparedness and response capabilities[150]. Shareholder and Equity Management - The company did not distribute cash dividends or issue bonus shares during the reporting period[14]. - The company plans to continue its strategy of not distributing cash dividends or increasing share capital from capital reserves in the near term[114]. - The company has a three-year unlocking plan for equity incentive shares, with unlocking ratios of 40%, 30%, and 30%[162]. - The total number of ordinary shareholders at the end of the reporting period is 21,130[165].

包头东宝生物技术股份有限公司 2020 年第一季度报告 2020-028 包头东宝生物技术股份有限公司 2020 年第一季度报告全文 2020 年 04 月 1 包头东宝生物技术股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王军、主管会计工作负责人郝海青及会计机构负责人(会计主管 人员)杜丽声明：保证季度报告中财务报表的真实、准确、完整。 2 包头东宝生物技术股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 89,993,866.50 | 113,291,169.46 | -20.56% | | 归属于上市公司股东的净利润（元） | 3,508,6 ...